Aeterna Zentaris Files June 2024 6-K Report

Ticker: CSCIF · Form: 6-K · Filed: Jun 25, 2024 · CIK: 1113423

Aeterna Zentaris INC. 6-K Filing Summary
FieldDetail
CompanyAeterna Zentaris INC. (CSCIF)
Form Type6-K
Filed DateJun 25, 2024
Risk Levellow
Pages4
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: 6-K, foreign-private-issuer, regulatory-filing

Related Tickers: AEZS

TL;DR

Aeterna Zentaris filed its June 6-K, confirming its foreign private issuer status and Toronto HQ.

AI Summary

Aeterna Zentaris Inc. filed a Form 6-K on June 25, 2024, reporting for the month of June 2024. The filing indicates the company is a foreign private issuer and files annual reports under Form 20-F. The principal executive office is located in Toronto, Ontario, Canada.

Why It Matters

This filing provides routine updates for investors and regulatory bodies regarding Aeterna Zentaris's status as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

FAQ

What is the primary purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign private issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of June 2024.

What is Aeterna Zentaris Inc.'s filing status regarding annual reports?

Aeterna Zentaris Inc. files annual reports under cover of Form 20-F.

Where is Aeterna Zentaris Inc.'s principal executive office located?

The principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.

What is the SEC file number for Aeterna Zentaris Inc.?

The SEC file number for Aeterna Zentaris Inc. is 001-38064.

What is the SIC code for Aeterna Zentaris Inc.?

The Standard Industrial Classification (SIC) code for Aeterna Zentaris Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,089 words · 4 min read · ~4 pages · Grade level 15 · Accepted 2024-06-25 15:36:18

Filing Documents

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-38064 Aeterna Zentaris Inc. (Translation of registrant’s name into English) c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Explanatory Note On June 24, 2024, Aeterna Zentaris Inc. (“Aeterna”, “we”, “our” or the “Company”) filed with the Canadian Securities Regulatory Authorities on SEDAR+ its Management Information Circular in connection with its Annual General and Special Meeting of Shareholders to be held on July 16, 2024 (the “Annual Meeting”), a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. On the same date, Aeterna also filed on SEDAR+ the notice of the Annual Meeting, the form of proxy for the Annual Meeting, and a certificate of abridgment with relation to the Annual Meeting, copies of which are attached hereto as Exhibit 99.2, 99.3 and 99.4, respectively, and are incorporated herein by reference Exhibit 99.1 included with this Report on Form 6-K is hereby incorporated by reference into Aeterna’s Registration Statements on Forms S-8 (No. 333-224737, No. 333-210561, No. 333-200834 and No. 333-279844) and Form F-3 (No. 333-254680) (collectively, the “Registration not superseded by documents or reports subsequently filed or furnished. The information contained on any websites referenced in Exhibit 99.1 included with this Report on Form 6-K is not incorporated by reference or deemed to be a part of this Report on Form 6-K or any of the Registration Statements. Forward-Looking The information in this Report on Form 6-K and the exhibit attached hereto and incorporated herein by reference include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause actual results and outcomes to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Forward-looking as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: Aeterna’s ability to raise capital and obtain financing to continue its currently planned operations; Aeterna’s ability to maintain compliance with the continued listing requirements of the NASDAQ and to maintain the listing of its common shares on the NASDAQ; Aeterna’s ability to continue as a going concern, which is dependent, in part, on its ability to transfer cash from Aeterna Zentaris GmbH to Aeterna and its U.S. subsidiary and to secure additional financing; Aeterna’s now heavy dependence on the success of Macrilen™ (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product, including its heavy reliance on the success of the license and assignment agreement with Novo Nordisk A/S; Aeterna’s ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect; Aeterna’s reliance on third parties for the manufacturing and commercialization of Macrilen™ (macimorelin); potential disputes with third parties, leading to delays in or termination of the manufacturing, development, out-licensing or commercialization of Aeterna’s product candidates, or resulting in significant litigation or arbitration; uncertainties related to the regulatory process; unforeseen global instability, including the instability due to the global pandemic of the novel coronavirus; Aeterna’s ability to efficiently commercialize or out-license Macrilen™ (macimorelin); Aeterna’s reliance on the success of the pediatric clinical trial in the European Union (“E.U.”) and U.S. for Macrilen™ (ma

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing